These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 7100242)

  • 1. [Investigations in Bioavailability of resinates as peroral retard drug dosage forms. Part 1: Pharmaceutical availability of dihydrocodein-resinates (author's transl)].
    Mühlenbruch B; Strauss H; Glaubitz H
    Pharmazie; 1982 Mar; 37(3):200-3. PubMed ID: 7100242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioavailability of ambroxol sustained release preparations. Part I: In vitro dissolution studies.
    Alighieri T; Avanessian S; Berlini S; Bianchi SG; Deluigi P; Valducci R; Guelen PJ
    Arzneimittelforschung; 1988 Jan; 38(1):92-4. PubMed ID: 3365281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulatory aspects of modified release dosage forms: special cases of dissolution testing using the flow-through system.
    Möller H; Wirbitzki E
    Boll Chim Farm; 1993 Apr; 132(4):105-15. PubMed ID: 8333916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Galenical possibilities and problems in protraction of drug effects (author's transl)].
    Müller F
    Arzneimittelforschung; 1976; 26(1A):115-21. PubMed ID: 7277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual ambroxal and chlorpheniramine resinate as an alternative carrier in concurrent resinate administration.
    Akkaramongkolporn P; Ngawhirunpat T
    Pharmazie; 2003 Mar; 58(3):195-9. PubMed ID: 12685813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Influence of formulation of enteric coated tablets on the bioavailability of the drug. 4th Part: Influence of the enteric polymer dissolution pH on the "in vivo" absorption of aspirin from coated tablets (author's transl)].
    Delporte JP; Jaminet F
    J Pharm Belg; 1976; 31(3):263-76. PubMed ID: 8603
    [No Abstract]   [Full Text] [Related]  

  • 7. Evaluation of the USP dissolution test method A for enteric-coated articles by planar laser-induced fluorescence.
    Miller DA; Gamba M; Sauer D; Purvis TP; Clemens NT; Williams RO
    Int J Pharm; 2007 Feb; 330(1-2):61-72. PubMed ID: 17034967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The effect of different variables on the in vitro dissolution of a theophylline sustained-release preparation].
    Fuchs WS; Jakobs R; Grunenberg P; Weiss G; Profitlich T; von Nieciecki A; Klemm FH; Laicher A; Stanislaus F
    Arzneimittelforschung; 1998 May; 48(5A):552-6. PubMed ID: 9676343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Reconstruction of dissolution profiles of microcapsulated formulations by the mean and variance of dissolution times (author's transl)].
    Brockmeier D
    Arzneimittelforschung; 1981; 31(10):1746-51. PubMed ID: 6895598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of a continuous fluid exchange system in the USP basket-stirrer dissolution test assembly. Part 11: Characterization of the dissolution profile of quinidine sustained-release dosage forms.
    Huynh-Ngoc T; Sirois Gérard
    J Pharm Belg; 1977; 32(1):67-75. PubMed ID: 16996
    [No Abstract]   [Full Text] [Related]  

  • 11. Reformulation of a codeine phosphate liquid controlled-release product.
    Roblegg E; Dittrich P; Haltmeyer K; Zimmer A
    Drug Dev Ind Pharm; 2010 Dec; 36(12):1454-62. PubMed ID: 20533890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of biorelevant dissolution tests to the prediction of in vivo performance of diclofenac sodium from an oral modified-release pellet dosage form.
    Jantratid E; De Maio V; Ronda E; Mattavelli V; Vertzoni M; Dressman JB
    Eur J Pharm Sci; 2009 Jun; 37(3-4):434-41. PubMed ID: 19491035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioavailability of indomethacin capsules in humans (II): correlation with dissolution rate.
    Aoyagi N; Ogata H; Kaniwa N; Ejima A
    Int J Clin Pharmacol Ther Toxicol; 1985 Oct; 23(10):529-34. PubMed ID: 4066077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory aspects of drug dissolution from a European perspective.
    Graffner C
    Eur J Pharm Sci; 2006 Nov; 29(3-4):288-93. PubMed ID: 16950606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diclofenac sodium multisource prolonged release tablets--a comparative study on the dissolution profiles.
    Bertocchi P; Antoniella E; Valvo L; Alimonti S; Memoli A
    J Pharm Biomed Anal; 2005 Apr; 37(4):679-85. PubMed ID: 15797788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Drug-drug interactions (author's transl)].
    Forth W
    Arzneimittelforschung; 1976; 26(1A):108-14. PubMed ID: 7276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of dissolution profiles obtained from nifedipine extended release once a day products using different dissolution test apparatuses.
    Garbacz G; Golke B; Wedemeyer RS; Axell M; Söderlind E; Abrahamsson B; Weitschies W
    Eur J Pharm Sci; 2009 Sep; 38(2):147-55. PubMed ID: 19591927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and optimization of the drug release determination of iron from iron prolonged release tablets.
    Kincl M; Bibic R; Veber M; Vrecer F
    Pharmazie; 2003 Apr; 58(4):257-9. PubMed ID: 12749408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A century of dissolution research: from Noyes and Whitney to the biopharmaceutics classification system.
    Dokoumetzidis A; Macheras P
    Int J Pharm; 2006 Sep; 321(1-2):1-11. PubMed ID: 16920290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel pH-dependent gradient-release delivery system for nitrendipine II. Investigations of the factors affecting the release behaviors of the system.
    Yang M; Cui F; You B; Wang L; Yue P; Kawashima Y
    Int J Pharm; 2004 Nov; 286(1-2):99-109. PubMed ID: 15501006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.